PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22333588-3	2012	We recently envisioned that intervention strategies aimed at reversing the bioenergetic signature of cancer cells (e.g., the antidiabetic biguanide metformin) should correct oncogene (e.g., HER2)-driven MHC-I defects, thus preventing immune escape of oncogene transformants.	Metformin	148-157	erb-b2 receptor tyrosine kinase 2	Homo sapiens	190-194	
22333588-4	2012	First, we explored how metformin treatment impacted mitochondrial biogenesis in cultured breast cancer cells overexpressing the membrane tyrosine kinase receptor HER2, the best-characterized downregulator of MHC-I.	Metformin	23-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166